Fernand Labrie
Publications
Page 6 of 8, showing 50 records out of 361 total, starting on record 251, ending on 300
| Publication | Category | Year |
|---|---|---|
| 111. Labrie, F., Dupont, A., Giguère, M., Borsanyi, J.P., Lacourcière, Y., Bélanger, A., Lachance, R., Emond, J., Monfette, G., Lachance, R. (1987) Combination therapy with Flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients. J. Steroid Biochem., 27: 525-532. | Prostate Cancer | 1987 |
| 110. Labrie, F., Luthy, I., Veilleux, R., Simard, J., Bélanger, A., Dupont, A. (1987) New concepts on the androgen sensitivity of prostate cancer, in: Murphy, G.P., Khoury, S., Kuss, R., Chatelain, C. et Denis, L., eds: Progress in Clinical and Biological Research. Prostate cancer Part A: Research. Endocrine treatment and histopathology, pp 145-172. | Prostate Cancer | 1987 |
| 109. Labrie, F., Poulin, R., Simard, J., Hubert, J.F., Spinola, P., Marchetti, B. (1987) Adrenal steroids exert potent estrogen action in both normal and cancer tissue, in: Klijn, J.G.M., Paridaens, R. et Foekens, J.A., eds: Hormonal Manipulation of Cancer: Peptides Growth Factors and New (Anti-) Steroidal Agents. Monograph Series of the European Organization for Research on Treatment of Cancer, New York, Raven Press, pp 7-16. | Prostate Cancer | 1987 |
| 108. Luthy, I., Labrie, F. (1987) Development of androgen resistance in mouse mammary tumor cells can be prevented by the antiandrogen flutamide. Prostate, 10: 89-94. | Prostate Cancer | 1987 |
| 107. Moorjani, S., Dupont, A., Labrie, F., Lupien, P.J., Brun, D., Gagné, C., Giguère, M., Bélanger, A. (1987) Increase in plasma high density lipoprotein concentration following complete androgen blockage in men with prostate cancer. Metabolism, 36: 244-250. | Prostate Cancer | 1987 |
| 106. Soret, J.Y., Verine, J.L., Daver, A., Labrie, F. (1987) Comparative results of the variations in intraprostatic androgen levels and androgen receptors following pulpectomy with or without an antiandrogen (Flutamide) in the treatment of advanced prostate cancer, in: Murphy, G.P., Khoury, S., Kreiss, R., Chatelain, C. et Denis, L., eds: Prostate Cancer Research, Endocrine Treatment and Histopathology. Progress in Clinical and Biological Research, New York, Alan R. Liss Inc., pp 77. | Prostate Cancer | 1987 |
| 105. Soret, Y., Verine, J.L., Daver, A., Labrie, F. (1987) Levels of intraprostatic androgen receptors and intraprostatic testosterone following orchiectomy with or without addition of an antiandrogen (Flutamide) in the treatment of advanced prostatic cancer. J. Drug Dev., 1: 23-25. | Prostate Cancer | 1987 |
| 104. Dubé, D., Poyet, P., Pelletier, G., Labrie, F. (1986) Radioautographic localization of ?-adrenergic receptors in the rat ventral prostate. J. Androl., 7: 169-174. | Prostate Cancer | 1986 |
| 103. Harnois, C., Malenfant, M., Dupont, A., Labrie, F. (1986) Ocular toxicity of Anandron in patients treated for prostatic cancer. Br. J. Ophthalmol., 70: 471-473. | Prostate Cancer | 1986 |
| 102. Labrie, F., Bélanger, A., Dupont, A., Emond, J., Lacourcière, Y., Monfette, G. (1986) Cancers évolués de la prostate: traitement par l'association d'un agoniste de la LHRH et d'un antiandrogène pur. J. Int. Med., 66: 367-368. | Prostate Cancer | 1986 |
| 101. Labrie, F., Dupont, A., Bélanger, A. (1986) Blocco totale degli androgeni nel trattamento del cancro della prostata. Essex Oncologia, 3-47. | Prostate Cancer | 1986 |
| 100. Labrie, F., Dupont, A., Bélanger, A. (1986) Combined therapy with an LHRH agonist and a pure antiandrogen in prostate cancer, in: Paulson, J.D., Negro-Vilar, A., Lucena, E. et Martini, L., eds: Andrology: Male Fertility and Sterility, New York, Academic Press, pp 39-55. | Prostate Cancer | 1986 |
| 99. Labrie, F., Dupont, A., Bélanger, A. (1986) LHRH analogues in prostate cancer. Lancet, Vol. I: 445-446. | Prostate Cancer | 1986 |
| 98. Labrie, F., Dupont, A., Bélanger, A., Lacourcière, Y., Giguère, M., Emond, J., Monfette, G. (1986) Traitement antiandrogénique combiné dans l'adénocarcinome de la prostate: première application d'un nouveau principe thérapeutique dans le cancer hormono-dépendant. Ann. Urol. (Paris), 20: 98-106. | Prostate Cancer | 1986 |
| 97. Labrie, F., Dupont, A., Bélanger, A., Poyet, P., Giguère, M., Lacourcière, Y., Emond, J., Monfette, G., Borsanyi, J.P. (1986) Combined treatment with Flutamide and surgical or medical (LHRH agonist) castration in metastatic prostatic cancer. Lancet, 327: 48-49. | Prostate Cancer | 1986 |
| 96. Labrie, F., Dupont, A., Bélanger, A., St-Arnaud, R., Giguère, M., Lacourcière, Y., Emond, J., Monfette, G. (1986) Combined treatment with an LHRH agonist and the antiandrogen Flutamide in prostate cancer, in: Moody, T.W., ed. Neural Endocrine Peptides and Receptors, New York, Plenum Press, pp 627-644. | Prostate Cancer | 1986 |
| 95. Labrie, F., Dupont, A., Bélanger, A., St-Arnaud, R., Giguère, M., Lacourcière, Y., Emond, J., Monfette, G. (1986) Treatment of prostate cancer with gonadotropin-releasing hormone agonists. Endocrine Rev., 7: 67-74. | Prostate Cancer | 1986 |
| 94. Labrie, F., Dupont, A., Emond, J., Monfette, G. (1986) Combination therapy in prostate cancer. Lancet, 2: 1095-1096. | Prostate Cancer | 1986 |
| 93. Labrie, F., Dupont, A., Emond, J., Monfette, G. (1986) Combination therapy in prostate cancer. Br. Med. J. (Clin. Res. Ed.), 293: 1171. | Prostate Cancer | 1986 |
| 92. Labrie, F., Dupont, A., Giguère, M., Borsanyi, A., Bélanger, A., Lacourcière, Y., Emond, J., Monfette, G. (1986) Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer. J. Steroid Biochem., 25: 877-883. | Prostate Cancer | 1986 |
| 91. Labrie, F., Veilleux, R. (1986) A wide range of sensitivities to androgens develops in cloned Shionogi mouse mammary tumor cells. Prostate, 8: 293-300. | Prostate Cancer | 1986 |
| 90. Lacourcière, Y., Dupont, A., Giguère, M., Labrie, F. (1986) L'utilité de la scintigraphie osseuse dans l'évaluation de l'atteinte squelettique du cancer de la prostate traité à l'aide d'une association LHRH-antiandrogènes. Union Med. Can., 115: 229-234. | Prostate Cancer | 1986 |
| 89. Poyet, P., Gagné, B., Labrie, F. (1986) Characteristics of the ?-adrenergic stimulation of adenylate cyclase activity in rat ventral prostate and its modulation by androgens. Prostate, 9: 237-245. | Prostate Cancer | 1986 |
| 88. Poyet, P., Gagné, B., Lavoie, M., Labrie, F. (1986) Characteristics of the ?-adrenergic receptor in the rat ventral prostate using [125I]cyanopindolol. Mol. Cell. Endocrinol., 48: 59-67. | Prostate Cancer | 1986 |
| 87. Raynaud, J.P., Coussedière, D., Moguilewsky, M., Pottier, J., Labrie, F. (1986) Cancer de la prostate: bases biologiques pour l'emploi d'un antiandrogène dans le traitement. Bulletin du Cancer, 73: 36-46. | Prostate Cancer | 1986 |
| 86. Simard, J., Luthy, I., Guay, J., Bélanger, A., Labrie, F. (1986) Characteristics of interaction of the antiandrogen Flutamide with the androgen receptor in various target tissues. Mol. Cell. Endocrinol., 44: 261-270. | Prostate Cancer | 1986 |
| 85. St-Arnaud, R., Lachance, R., Dupont, A., Labrie, F. (1986) Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-treated patients treated with an LH-releasing hormone agonist and antiandrogen. J. Clin. Endocrinol. Metab., 63: 297-302. | Prostate Cancer | 1986 |
| 84. St-Arnaud, R., Lachance, R., Dupont, A., Labrie, F. (1986) Stimulation of the circulating levels of glycoprotein hormone alpha-subunit after combined administration of a luteinizing hormone-releasing hormone (LHRH) agonist and Flutamide in patients with cancer of the prostate. Clin. Invest. Med., 9: 215-221. | Prostate Cancer | 1986 |
| 83. St-Arnaud, R., Lachance, R., Kelly, S.J., Bélanger, A., Dupont, A., Labrie, F. (1986) Loss of luteinizing hormone (LH) bioactivity in patients with prostatic cancer treated with an LHRH agonist and a pure antiandrogen. Clin. Endocrinol. (Oxf.), 24: 21-30. | Prostate Cancer | 1986 |
| 82. Labrie, F. (1985) Dreijahrige erfahrungen mit der Kombinations-therapie von Flutamid und einem LHRH-agonisten leuprolide beim Prostatakarzinom. Der Urologe. Ausg. B., B6: 342-343. | Prostate Cancer | 1985 |
| 81. Labrie, F. (1985) LHRH et ses agonistes: applications thérapeutiques. Médecine/Sciences, 1: 300-305. | Prostate Cancer | 1985 |
| 80. Labrie, F., Dupont, A., Bélanger, A. (1985) Complete androgen blockade for the treatment of prostate cancer, in: DeVita, V.T., Hellman, S. et Rosenberg, S.A., eds: Important Advances in Oncology, Philadelphia, J.B. Lippincott, pp 193-217. | Prostate Cancer | 1985 |
| 79. Labrie, F., Dupont, A., Bélanger, A., Giguère, M., Lacourcière, Y., Emond, J., Monfette, G., Bergeron, V. (1985) Combination therapy with Flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. J. Steroid Biochem., 23: 833-841. | Prostate Cancer | 1985 |
| 78. Labrie, F., Dupont, A., Bélanger, A., Lachance, R., Giguère, M. (1985) Long-term treatment with luteinizing hormone-releasing hormone agonists and maintenance of serum testosterone to castration concentrations. Br. Med. J. (Clin. Res. Ed.), 291: 369-370. | Prostate Cancer | 1985 |
| 77. Labrie, F., Dupont, A., Bélanger, A., Lacourcière, Y., Emond, J., Monfette, G., Bergeron, V. (1985) Antiandrogènes et agonistes de la LHRH dans le traitement du cancer de la prostate. Médecine/Sciences, 1: 435-439. | Prostate Cancer | 1985 |
| 76. Perez, C.A., Fair, W.R., Ihde, D.C., Labrie, F. (1985) Cancer of the prostate, in: De Vita, V.T., Hellman, S. et Rosenberg, C., eds: Cancer: Principles and Practice of Oncology, Philadelphia, J.P. Lippincott, pp 929-964. | Prostate Cancer | 1985 |
| 75. Poyet, P., Labrie, F. (1985) Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate. Mol. Cell. Endocrinol., 42: 283-288. | Prostate Cancer | 1985 |
| 74. Raynaud, J.P., Moguilewsky, M., Tournemine, C., Pottier, J., Coussedière, D., Salmon, J., Husson, J.M., Bertagna, C., Tremblay, D., Pendyala, L., Brisset, J.M., Vallancien, G., Serment, G., Navratil, N., Dupont, A., Labrie, F. (1985) Pharmacology and clinical studies with RU23908 (Anandron). EORTC Genitourinary Group Monograph 2, Part A, in: Schroeder, F.H. et Richards, B., eds: Therapeutic Principles Metastatic Protastic Cancer, New York, Alan R. Liss Inc., pp 99-120. | Prostate Cancer | 1985 |
| 73. Bélanger, A., Dupont, A., Labrie, F. (1984) Inhibition of basal and adrenocorticotropin-stimulated plasma levels of adrenal androgens after treatment with an antiandrogen in castrated patients with prostatic cancer. J. Clin. Endocrinol. Metab., 59: 422-426. | Prostate Cancer | 1984 |
| 72. Bélanger, A., Tremblay, Y., Lacoste, D., Giasson, M., Dupont, A., Labrie, F. (1984) The dog, a good model for the study of LHRH agonists as blockers of androgen secretion and potential contraceptives, in: Labrie, F., Bélanger, A. et Dupont, A., eds: Proceedings of the International Symposium on LHRH and its Analogues: Basic and Clinical Aspects, New York, Excerpta Medica, pp 141-155. | Prostate Cancer | 1984 |
| 71. Faure, N., Lemay, A., Tolis, G., Labrie, F., Bélanger, A., Fazekas, A.T.A. (1984) Buserelin therapy for prostatic carcinoma, in: Vickery, B.H., Nestor, J.J. et Hafez, E.S.E., eds: LHRH and its analogs: contraceptive and therapeutic applications, Boston, MTP Press, pp 337-349. | Prostate Cancer | 1984 |
| 70. Labrie, F. (1984) A new approach in the hormonal treatment of prostate cancer: complete instead of partial blockade of androgens. Int. J. Androl., 7: 1-4. | Prostate Cancer | 1984 |
| 69. Labrie, F. (1984) Résultats exceptionnels d'un nouveau traitement du cancer de la prostate. Interface, 5: 23-25. | Prostate Cancer | 1984 |
| 68. Labrie, F., Bélanger, A., Dupont, A., Emond, J., Lacourcière, Y., Monfette, G. (1984) Combined treatment with an LHRH agonist and a pure antiandrogen in advanced carcinoma of prostate. Lancet, 2: 1090. | Prostate Cancer | 1984 |
| 67. Labrie, F., Bélanger, A., Dupont, A., St-Arnaud, R. (1984) Medical castration in men: the first clinical application of LHRH agonists, in: Harrison, R.F. et Thompson, B.J., eds: Fertility and Sterility, MTP Press, pp 25-39. | Prostate Cancer | 1984 |
| 66. Labrie, F., Dupont, A., Bélanger, A. (1984) Complete androgen neutralization is most important in the treatment of prostate cancer, in: Harrap, K.R., Davis, W. et Calvert, A.H., eds: Cancer Chemotherapy and Selective Drug Development, Martinus Nijihoff Publishing, pp 475-479. | Prostate Cancer | 1984 |
| 65. Labrie, F., Dupont, A., Bélanger, A. (1984) Un nouveau traitement du cancer de la prostate: la suppression complète des androgènes, in: Mauvais-Jarvis, P. et Schaison, G., eds: Médecine de la reproduction masculine, Flammarion, Presses Université de Montréal, pp 367-383. | Prostate Cancer | 1984 |
| 64. Labrie, F., Dupont, A., Bélanger, A., Emond, J., Monfette, G. (1984) Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer. Proc. Natl. Acad. Sci. USA, 81: 3861-3863. | Prostate Cancer | 1984 |
| 63. Labrie, F., Dupont, A., Bélanger, A., Labrie, C., Lacourcière, Y., Emond, J., Monfette, G., Houle, J.G., Girard, J.G., Vallières, A., Bossé, C., Delisle, R. (1984) Dramatic response of prostate cancer to complete antihormonal treatment, in: Bracci, U. et Silverio, F.D., eds: Advances in Urological Oncology and Endocrinology, Rome, Acta Medica, Edizione E Congressi, pp 233-248. | Prostate Cancer | 1984 |
| 62. Labrie, F., Dupont, A., Bélanger, A., Labrie, C., Lacourcière, Y., Raynaud, J.P., Husson, J.M., Emond, J., Houle, J.G., Girard, J.G., Monfette, G., Paquet, J.P., Vallières, A., Bossé, C., Delisle, R. (1984) Combined antihormonal treatment in prostate cancer: a new approach using an LHRH agonist or castration and an antiandrogen, in: Bresciani, F., King, R.J.B., Lippman, M.E. et Raynaud, J.P., eds: Hormones and cancer 2: Proceedings of the Second International Congress on Hormones and Cancer, New York, Raven Press, pp 533-547. | Prostate Cancer | 1984 |